Mandate Also Includes Collaboration with Local Hospital for Innovative Surgical and Anti-Aging Procedures
TORONTO, ON / ACCESSWIRE / May 15, 2017 / EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company that develops innovative pharmaceutical products and produces and distributes innovative and healthy nutraceuticals based on natural therapies has announced that it has engaged the services of an agent affiliated with the Philippines pharmaceutical industry to seek out suitable joint venture partners and suppliers in the Philippines.
The agent, Roger Munoz, a principal of i-Power Philippines, a subsidiary of the ICube Group (www.icube.ph) a large holding group mostly for Nippon SME business in the Philippines, will work together with the company's own Global Business Development team to act in EastGate's interests in identifying local partners for the purposes of clinical testing, registration and marketing of the company's diabetes-cardiovascular related products including its OTC products and the pharmaceutical product pipeline being developed by EastGate (www.EastGateBiotech.com).
According to the World Health Organization, the Philippines is considered a diabetes hotspot. Presently, 1 out of every 5 Filipinos has diabetes representing 20% of the population. It is predicted that the Philippines will be part of the top 10 countries affected by diabetes due to the accelerated rate of its citizens developing the disease.
The agent, also has a mandate within his own personal capacity to establish collaborations with local hospitals looking to introduce innovative anti-aging treatments and surgical procedures to be provided by EastGate's wholly-owned subsidiary, OMNI Surgery + Anti-Aging Center (www.OmniSurgery.ca). The agent is already collaborating with a local Neurologist specialist for the purpose of attracting innovation to the Philippines.
"We are excited about establishing Joint Venture partnerships in this emerging and growing Philippines market," states Anna Gluskin, EastGate's CEO. "This effort will complement our ongoing business development activities and inroads in other densely-populated diabetes countries in the SEA region. From our early discussions that have been initiated in the Philippines and due to the growing concern for disease management we anticipate that we will be able to enter into productive and viable partnerships in the Philippines soon," concluded Gluskin.
About EastGate Biotech
EastGate Biotech develops innovative pharmaceutical products and produces and distributes innovative and healthy nutraceuticals that are based on natural therapies and absorbed naturally by the body. We utilize advanced nanotechnologies to delivery healthy alternatives to conventional pharmaceuticals that all-too-often create dangerous side-effects and unexpected consequences for those trying to attain and maintain healthy lives.
Our research and development team are dedicated to providing the best nutraceutical products and pharmaceutical products for your natural comfort, health and well-being. We invite you to explore the naturally healthy benefits of EastGate Biotech (www.EastGateBiotech.com).
About OMNI Surgery + Anti-Aging Centre-EastGate's Wholly-Owned Subsidiary
OMNI is a fee-for-service, Surgery + Anti-Aging Centre offering plastic, orthopaedic, along with general surgical procedures. Alongside the surgical procedures, the Anti-Aging Centre is equipped with State-of-the-Art technology that work to contour, tone, and remove blemishes in order to reverse the aging process. As a Centre of Excellence in Saskatchewan, OMNI's board-certified surgeons work to deliver high-quality care mindful of patients' needs, while helping them achieve the results they want.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbour" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates", "forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential", "projected", "pursue", "strategy", "study", "targets", or "believes", or variations of or similar such words and phrases or statements that certain actions, events or results "may", "could", "would", or "should", "might", or "way forward", "will be taken", "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Rose Perri
1-647-692-0652
Email: [email protected]
Website: www.EastGateBiotech.com
SOURCE: EastGate Biotech